Loading
A phase 2/3 trial testing D07001 in biliary tract cancer, now recruiting.
Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer is a phase 2/3 interventional study registered as NCT05065957, led by InnoPharmax, and recruiting on the registry. Official title: Open-Label, Multicenter, Phase II/III Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer After Gemcitabine and Cisplatin-Based Treatment Failure. Planned enrolment is 180 participants (estimated). The study started in 2022-03-29 and primary completion is expected in 2026-07. No results have been posted on ClinicalTrials.gov.